Adeza to Present at Investment Community Conferences
01 Septiembre 2006 - 1:35PM
Business Wire
Adeza (NASDAQ: ADZA) today announced that Emory V. Anderson,
president and chief executive officer, will make investment
community presentations at two conferences: -- The Thomas Weisel
Partners Healthcare Conference 2006 on Wednesday, September 6, at
10:20 a.m. Eastern time (7:20 a.m. Pacific time). This conference
will be held at the Four Seasons Hotel in Boston. For more
information visit www.tweisel.com. -- The Roth Capital Partners
2006 New York Conference on Thursday, September 7, at 11:00 a.m.
Eastern time (8:00 a.m. Pacific time). This conference will be held
at the Westin New York at Times Square. For more information about
this conference visit www.rothconference.com. Live audio and slide
webcasts of these presentations will be available via the Internet
by visiting the Investor Relations section of the company's Web
site at www.adeza.com. An archive of each presentation will be
available on the company's Web site for 14 days. About Adeza Adeza
designs, manufactures and markets innovative products for women's
health. Adeza's initial focus is on reproductive healthcare using
its proprietary technologies to predict preterm birth and assess
infertility. Adeza's principal product is a patented diagnostic
test, FullTerm(TM), The Fetal Fibronectin Test, which utilizes a
single-use, disposable cassette and is analyzed on Adeza's patented
TLiIQ(R) System. This product is approved by the U.S. Food and Drug
Administration (FDA) for use in assessing the risk of preterm
birth. Adeza also markets and sells the E-tegrity(R) Test, an
infertility-related test to assess receptivity of the uterus to
embryo implantation in women with unexplained infertility. In May
2006, Adeza announced the submission of its New Drug Application
(NDA) to the FDA for Gestiva(TM), a long-acting form of a naturally
occurring progesterone to prevent preterm birth in women with a
history of preterm delivery. On August 29, 2006, the Reproductive
Health Drugs Advisory Committee to the FDA recommended by majority
vote that the data presented by Adeza in its NDA support efficacy
in preventing preterm birth prior to 35 weeks and that overall
safety data was adequate and sufficiently reassuring to support
marketing approval of Gestiva for women with a history of preterm
delivery. The Advisory Committee also recommended the collection of
post-marketing clinical data. Although Advisory Committee
recommendations are not binding, typically FDA final determinations
are consistent with their recommendations. Pursuant to Prescription
Drug User Fee Act (PDUFA) guidelines, the FDA has a goal to
complete its review or otherwise respond to the Gestiva NDA by
October 20, 2006. More information is available at www.adeza.com.
Adeza cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements, including for example, statements related to Gestiva's
regulatory status and medical potential. The inclusion of
forward-looking statements should not be regarded as a
representation by Adeza that any of its plans will be achieved.
Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in Adeza's
business including, without limitation, risks related to the
anticipated regulatory or commercial path for its product
candidates. Further information about these and other risks is
included Adeza's Annual Report on Form 10-K and other periodic and
current reports filed by Adeza with the Securities and Exchange
Commission, which are available from the SEC's Web site
(www.sec.gov), and also available on the Investor Relations section
of Adeza's Web site. All forward-looking statements are qualified
in their entirety by this cautionary statement and Adeza undertakes
no obligation to revise or update this news release to reflect
events or circumstances after the date hereof.
Adeza (NASDAQ:ADZA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Adeza (NASDAQ:ADZA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Adeza Biomedical (MM) (NASDAQ): 0 recent articles
Más de Adeza ArtÃculos de Noticias